For the Inventor, By the Inventor

Enter assignee name

Berlin, Germany

Noxxon Pharma Ag

USPTO Granted Patents = 31

CIPO Patents = 2

EPO Patents = 15

Trademarks = 2

Forward Citations = 120

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Sven Klussmann (28 out of 32 patents)

Christian Maasch (23 out of 26 patents)

Florian Jarosch (20 out of 22 patents)

4. Klaus Buchner (19 out of 21 patents)

5. Werner Purschke (19 out of 20 patents)

6. Dirk Eulberg (18 out of 18 patents)

7. Axel Vater (8 out of 12 patents)

8. Nicole Dinse (8 out of 8 patents)

9. Kai Hohlig (4 out of 7 patents)

10. Dirk Zboralski (3 out of 5 patents)

11. Steffen Helmling (3 out of 3 patents)

12. Lucas Bethge (2 out of 12 patents)

13. Simone Sell (2 out of 2 patents)

14. Frank Schwobel (2 out of 2 patents)

15. Bernd Eschgfäller (2 out of 2 patents)

31 patents: Sort by Forward Citations

1. 11459352 - Method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent (2022-10-04),

2. 11371045 - Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors (2022-06-28),

3. 10590424 - C5a binding nucleic acids (2020-03-17),

4. 10513536 - Methods for the preparation of a polyalkoxylated nucleic acid molecule (2019-12-24),

5. 10273480 - MCP-1 binding nucleic acids (2019-04-30),

6. 10093934 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2018-10-09),

7. 9988636 - SDF-1 binding nucleic acids and the use thereof (2018-06-05),

8. 9976145 - Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same (2018-05-22),

9. 9850471 - Enzymatic synthesis of L-nucleic acids (2017-12-26),

10. 9822369 - SDF-1 binding nucleic acids (2017-11-21),

11. 9670491 - MCP-1 binding nucleic acids (2017-06-06),

12. 9518265 - C5a binding nucleic acids (2016-12-13),

13. 9387221 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2016-07-12),

14. 9163243 - Nucleic acids specifically binding CGRP (2015-10-20),

15. 9074214 - Use of spiegelmers (2015-07-07),

NOXXON Pharma AG is a clinical-stage biopharmaceutical company focused on developing cancer therapies using its proprietary Spiegelmer® platform. Spiegelmers are synthetic, completely chemically defined, L-stereoisomer RNA oligonucleotides, which can be designed to bind with high specificity and affinity to target molecules, blocking or modulating their functions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

31 Patents

#30 in D-1000 Berlin

#1,595 in Germany

#20,639 in the World

Berlin, Germany

Noxxon Pharma Ag

Forward Citations = 120

33 inventors:

Sven Klussmann (28 out of 32 patents)

Christian Maasch (23 out of 26 patents)

Florian Jarosch (20 out of 22 patents)

4. Klaus Buchner (19 out of 21 patents)

5. Werner Purschke (19 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…